ALMDP.PA Medesis Pharma EURONEXT €0.35 intraday Feb 19 2026: Oversold bounce

The ALMDP.PA stock is trading €0.35 on EURONEXT intraday on 19 Feb 2026, showing a high intraday print of €0.40 and heavy volume of 149,072 shares. This intraday activity meets classic oversold-bounce criteria: low price relative to 52-week range, elevated relative volume 9.37x, and clustered support near €0.30. We use Meyka AI as an AI-powered market analysis platform to show why short-term traders are watching a potential rebound.

Intraday price action and volume: ALMDP.PA stock technical snapshot

ALMDP.PA stock opened at €0.34 and trades between €0.335 and €0.397 today. Volume is 149,072 versus an average of 15,909, a relative volume of 9.37, which often precedes a sharp intraday mean reversion. High volume on a low-price base supports an oversold bounce hypothesis.

Valuation and fundamentals: ALMDP.PA stock financials

Medesis Pharma reports EPS -0.59 and a negative PE around -0.59, reflecting clinical-stage losses. Market cap stands at €1,801,314.00 with 5,146,610 shares outstanding. The company shows a low cash per share of €0.01 and a current ratio of 0.38, indicating funding risk despite IP and pipeline assets.

Sector context and catalysts: ALMDP.PA stock in Healthcare

The Healthcare sector on Europe exchanges has an average PE of 31.18 and positive YTD performance 2.23%. Medesis Pharma operates in Biotechnology where investor flows favor clear clinical readouts. Recent competitor coverage is available for context from investing.com comparisons to peers source and source.

Meyka AI grading and technical read: ALMDP.PA stock analysis

Meyka AI rates ALMDP.PA with a score out of 100: 64.88 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Technicals show price below the 50-day average (€0.37) and 200-day average (€0.50), a setup common before short-term rebounds in thinly traded biotechs.

Risk and opportunity: ALMDP.PA stock trading strategy

Upside catalysts include positive trial news, licensing deals, or a funding announcement; downside is dilution risk and weak liquidity outside spikes. Short-term traders can target a bounce to €0.50 first resistance, with stop-loss near €0.30 to limit downside. Institutional investors should focus on cash runway and pipeline milestones.

Price targets and model forecast: ALMDP.PA stock outlook

Meyka AI’s forecast model projects a 3-month target of €0.55 versus the current €0.35, an implied upside of 57.14%. A 12-month model scenario shows €1.20, an implied upside of 242.86%. Forecasts assume successful trial progress or capital raises; forecasts are model-based projections and not guarantees. For live quotes and more, see the Medesis page on Meyka Medesis on Meyka.

Final Thoughts

Key takeaways for the ALMDP.PA stock on EURONEXT intraday 19 Feb 2026: the share price at €0.35 sits near recent lows with a clear oversold setup and unusually high volume of 149,072, which supports the case for a short-term bounce. Fundamental risks remain: EPS -0.59, low cash per share €0.01, and a weak current ratio 0.38. Our technical plan for traders is a measured long on strength above €0.40 targeting €0.50 and €0.55 near-term, with a hard stop under €0.30. Meyka AI’s model projects €0.55 in three months (implied 57.14% upside) and €1.20 at 12 months (implied 242.86%), but forecasts are model-based projections and not guarantees. Use position sizing and expect high volatility in this biotechnology name.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.